281 related articles for article (PubMed ID: 15609328)
1. Exosomes: a new delivery system for tumor antigens in cancer immunotherapy.
Cho JA; Yeo DJ; Son HY; Kim HW; Jung DS; Ko JK; Koh JS; Kim YN; Kim CW
Int J Cancer; 2005 Apr; 114(4):613-22. PubMed ID: 15609328
[TBL] [Abstract][Full Text] [Related]
2. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.
Hsu DH; Paz P; Villaflor G; Rivas A; Mehta-Damani A; Angevin E; Zitvogel L; Le Pecq JB
J Immunother; 2003; 26(5):440-50. PubMed ID: 12973033
[TBL] [Abstract][Full Text] [Related]
3. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.
Kovjazin R; Volovitz I; Kundel Y; Rosenbaum E; Medalia G; Horn G; Smorodinsky NI; Brenner B; Carmon L
Vaccine; 2011 Jun; 29(29-30):4676-86. PubMed ID: 21570434
[TBL] [Abstract][Full Text] [Related]
4. Nanovesicular vaccines: exosomes.
Li X; Zhang Z; Beiter T; Schluesener HJ
Arch Immunol Ther Exp (Warsz); 2005; 53(4):329-35. PubMed ID: 16088317
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
6. MHC independent anti-tumor immune responses induced by Hsp70-enriched exosomes generate tumor regression in murine models.
Cho JA; Lee YS; Kim SH; Ko JK; Kim CW
Cancer Lett; 2009 Mar; 275(2):256-65. PubMed ID: 19036499
[TBL] [Abstract][Full Text] [Related]
7. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
8. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
9. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
10. Exosomal cancer immunotherapy is independent of MHC molecules on exosomes.
Hiltbrunner S; Larssen P; Eldh M; Martinez-Bravo MJ; Wagner AK; Karlsson MC; Gabrielsson S
Oncotarget; 2016 Jun; 7(25):38707-38717. PubMed ID: 27231849
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer.
Shi X; Sun J; Li H; Lin H; Xie W; Li J; Tan W
Prostate; 2020 Aug; 80(11):811-823. PubMed ID: 32427375
[TBL] [Abstract][Full Text] [Related]
12. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.
Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA
Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121
[TBL] [Abstract][Full Text] [Related]
13. [Exosome: Trojan horse in immunotherapy].
Mou DL; Jia ZS; Bai XF
Sheng Li Ke Xue Jin Zhan; 2005 Apr; 36(2):113-8. PubMed ID: 16222969
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of human neuroblastoma.
Prigione I; Corrias MV; Airoldi I; Raffaghello L; Morandi F; Bocca P; Cocco C; Ferrone S; Pistoia V
Ann N Y Acad Sci; 2004 Dec; 1028():69-80. PubMed ID: 15650233
[TBL] [Abstract][Full Text] [Related]
15. In vivo bioluminescence visualization of antitumor effects by human MUC1 vaccination.
Jeon YH; Choi Y; Kim HJ; Kang JH; Kim CW; Jeong JM; Lee DS; Chung JK
Mol Imaging; 2007; 6(5):297-303. PubMed ID: 18092514
[TBL] [Abstract][Full Text] [Related]
16. The immunogenicity of dendritic cell-derived exosomes.
Quah BJ; O'Neill HC
Blood Cells Mol Dis; 2005; 35(2):94-110. PubMed ID: 15975838
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.
Alajez NM; Schmielau J; Alter MD; Cascio M; Finn OJ
Blood; 2005 Jun; 105(12):4583-9. PubMed ID: 15746083
[TBL] [Abstract][Full Text] [Related]
19. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
[TBL] [Abstract][Full Text] [Related]
20. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines.
Nair SK; Boczkowski D; Snyder D; Gilboa E
Eur J Immunol; 1997 Mar; 27(3):589-97. PubMed ID: 9079797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
